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ABSTRACT
Objective To compare the effectiveness of subacromial
corticosteroid injection combined with timely exercise
and manual therapy (injection plus exercise) or exercise
and manual therapy alone (exerciseonly) in patients with
subacromial impingement syndrome.
Design Pragmatic randomised clinical trial.
Setting Primary care based musculoskeletal service.
Patients Adults aged 40 or over with subacromial
impingementsyndromewithmoderateorsevereshoulder
pain.
Interventions Injection plus exercise or exercise only.
Main outcome measures Primary outcome was the
difference in improvement in the total shoulder pain and
disability index at 12 weeks.
Results 232 participants were randomised (115 to
injection plus exercise, 117 to exercise only). The mean
age was 56 (range 40-78), 127 were women, and all had
had a median of 16 weeks of shoulder pain (interquartile
range 12-28). At week 12 there was no significant
differencebetweenthegroupsinchangeintotalpainand
disability index (mean difference between change in
groups 3.26 (95% confidence interval −0.81 to 7.34),
P=0.116). Improvement was significantly greater in the
injection plus exercise group at week 1 (6.56, 4.30 to
8.82) and week 6 (7.37, 4.34 to 10.39) for the total pain
and disability index (P<0.001), with no differences at
week 24 (−2.26, −6.77 to 2.25, P=0.324).
ConclusionsInthetreatmentofpatientswithsubacromial
impingement syndrome, injection plus exercise and
exercise only are similarly effective at 12 weeks.
Trial registration ISRCT 25817033; EudraCT No 2005-
003628-20.
INTRODUCTION
Shoulder pain is common in primary care, accounting
for11-12per1000generalpracticeconsultations.
1Pre-
valence increases with age, peaking at around age 50.
2
Shoulderpainisoftenpersistent,withonly50%report-
ing recovery after 18 months.
3 Subacromial impinge-
mentsyndrome(definedwithNeercriteria)isreported
to be the most common diagnosis.
14-6
Several well designed studies in primary care have
evaluated the broader concept of “shoulder pain.”
7-9
Common non-operative treatments include exercise,
manual therapy, and corticosteroid injections.
10-16
With respect to subacromial impingement syndrome
in particular, recent systematic reviews have found
beneficial effects with exercise and manual therapy
and with corticosteroid injections.
1718 No large trials
have evaluated the combination of these treatments,
possiblybecauseintraditionalmodelsofservicedeliv-
ery corticosteroid injections are deliveredby a general
practitioner and exercise or manual therapy by physio
therapists.
7-9
Wehypothesisedthattheuseofexerciseandmanual
therapy in the “window” of reduced pain after a corti-
costeroid injection could result in better outcomes for
people with subacromial impingement syndrome.
Electromyographic studies have shown that shoulder
pain inhibits the rotator cuff muscles and that effective
pain relief from subacromial injection of local anaes-
thetic can improve findings.
19 As these two treatments
probably work by different mechanisms, the com-
bined treatment approach could be more effective
than the single components. Using physiotherapists
to deliver both treatments, we examined the short
and long term effectiveness of local corticosteroid
injection combined with timely exercise and manual
therapy compared with exercise and manual therapy
alone for people with subacromial impingement syn-
drome in primary care.
METHODS
We used a pragmatic approach to reflect how treat-
ment is delivered in normal clinical practice. We
recruited participants from March 2006 to August
2008. Shoulder pain was defined as pain in the
shoulder region, including the upper arm, elicited or
exacerbated by active or passive shoulder movement.
To be included patients had to be aged 40 and older,
have unilateral shoulder pain, subjectively rate their
pain as moderate or severe on a 3 point scale (mild/
moderate/severe), and have a non-capsular pattern of
restriction.Capsularpatternwasdefinedaspainfuland
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BMJ | ONLINE FIRST | bmj.com page 1 of 7limited passive glenohumeral mobility, with lateral
rotation relatively more restricted than abduction and
medial rotation. This pragmatic definition has been
used in a previous study and is based on guidelines
from the Dutch College of General Practitioners.
8
Some loss of lateral rotation was permitted but no
morethan25%comparedwithoppositeside.
20Partici-
pants also had to show a Neer impingement sign (pas-
sive shoulder elevation with scapular fixed) or have
positive results on the Hawkins impingement test
(shoulder elevation to 90°, elbow flexed to 90°, then
passively internally rotate the humerus).
2122
Exclusion criteria were known blood coagulation
disorders; evidence of referred pain from the cervical
spine or internal organs; history of rheumatoid arthri-
tis, polymyalgia rheumatica, or other inflammatory
arthritis; bilateral shoulder pain; neurological diagno-
sis such as cerebrovascular event with shoulder invol-
vement; contraindication to steroid-lidocaine
injection; pregnancy or breast feeding; previous frac-
ture, dislocation, or surgery to shoulder, upper limb,
neck, or thorax; steroid injections or physiotherapy
for the symptomatic shoulder within the previous six
months; or inability to provide informed consent.
One author(DPC) and a researchassistant recruited
potentially eligible participants after screening
referrals from general practitioners to the Leeds Mus-
culoskeletalandRehabilitationService,aprimarycare
based musculoskeletal service. Once consent was
obtained, baseline outcome measures, including
demographic variables and potential prognostic vari-
ables,wererecorded.Simpleblockrandomisationwas
performed for seven sites based on a computer gener-
ated randomisation list. We then randomised partici-
pants to one of the two treatment groups using an
independent telephone randomisation service and
booked appointments to start treatment according to
allocation. While awaiting their first treatment
appointment, all participants were taught a home pro-
grammeofpendularexercises,whichinvolveswinging
the shoulder forwards and backwards or in a circular
motion while letting the arm hang down.
Interventions
The two study arms were subacromial corticosteroid
injection combined with exercise and manual therapy
(referred to subsequently as injection plus exercise) or
exercise and manual therapy alone (the exercise only
group). DPC and SJA delivered training on the study
arms to the study physiotherapists in a standardised
two hour training session. The study physiotherapists
were also given a trial manual to reinforce the study
protocol. Participants allocated to the injection plus
exercise group were injected with a lateral approach
at the mid-point of the acromion with 20 mg triamci-
nolone acetonide mixed with 4.5 ml 1% lidocaine
(lignocaine).
23Physiotherapistswithadiplomaininjec-
tion therapy performed all injections under a “patient
specific direction.” The injection could be repeated
after six weeks in patients with ongoing moderate to
severe pain.
Both groups were given standard advice to avoid
activities that caused or provoked pain; stop all sport-
ing activity and training; avoid using the arm for over-
head activities; and avoid repetitive movements or
activities that could have contributed to the shoulder
symptoms for one week.
Both groups received a programme delivered by a
physiotherapistthatstartedoneweekafterthesubacro-
mialinjectionorimmediatelyintheexerciseonlyarm.
The study coordinator, study physiotherapists, and a
nationalopinionleader(ashoulderphysiotherapyspe-
cialist) agreed the content of the physiotherapy inter-
vention at a consensus meeting. The intervention
comprised manual mobilisation techniques and exer-
cises, selected from a range of commonly used proce-
dures (see appendix on bmj.com). To individualise
treatments, the treating physiotherapists chose mobili-
sation techniques and exercises for each patient from
sixmobilisationtechniquesand23exercises.Exercises
were progressive as deemed appropriate by the treat-
ing physiotherapist. Resistive exercises were avoided
for two weeks after the corticosteroid injection in line
with professional guidelines.
24 The treating therapist
was asked to include a manual therapy technique at
least once over the course of the participant’s treat-
ment. Manual therapy is the application of specific
Not willing to be screened (n=436) Willing to be screened (n=1152)
Referred with shoulder pain (n=1588)
Eligible and randomised (n=232)
Exercise only (n=117) Subacromial injection plus exercise (n=115)
Given exercise (n=116) Received injection (n=114)
Given exercise (n=113)
Did not receive exercise
because of non-attendance (n=1)
Did not receive injection plus exercise because
  of non-attendance (n=1)
Did not attend for exercise after injection (n=2)
Not eligible (n=920):
  Age <40 (n=166)
  Mild shoulder pain (n=152)
  Lost more than 25% lateral rotation (n=156)
  Contraindications to steroid or lidocaine injection (n=22)
  Evidence of referred pain (n=79)
  Inflammatory arthritis (n=21)
  Bilateral shoulder pain (n=92)
  Previous fracture or dislocation (n=60)
  Previous physiotherapy or injection in past 6 months (n=144)
  Neurological abnormality (n=7)
  Negative impingement tests (n=20)
  Unable to give informed consent (n=1)
Follow-
up:
Lost to
follow-up
Week 1
Week 6
Week 12
Week 24
1
3
8
13
Did not
attend
9
13
7
0
Index
incomplete
1
0
1
6
Included
in analysis
104
99
99
96
Follow-
up:
Lost to
follow-up
Week 1
Week 6
Week 12
Week 24
1
2
6
13
Did not
attend
7
11
5
0
Index
incomplete
1
1
0
7
Included
in analysis
108
103
106
97
Recruitment flowchart, including reasons for non-inclusion and exclusion
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tissues. It was included as some research has shown
that combined with exercise this is more effective
than exercise alone.
2526 The patients attended as
many sessions as deemed necessary by the treating
physiotherapist.Weascertainedthenumberofpartici-
pantsreceivingthetrialinterventionsinthetwogroups
from the physiotherapy records and the therapy log
sheet completed by the treating physiotherapist.
Outcome measures
The primary outcome measure was the shoulder pain
and disability index (SPADI) at 12 weeks.
27 Scores
range from 0-100 for each of two subscales represent-
ing pain and disability. A total score is obtained by
taking the mean of these two subscale scores; a score
of 100 indicates severe pain and disability. We
included global assessment of change compared with
baseline (a five point scale of “complete recovery” to
“muchworse”)
7asasecondaryoutcomemeasure.Out-
comes were measured by self completed question-
naires at baseline and at one, six, and 12 weeks; a staff
member other than the treating physiotherapist pro-
vided the questionnaires. The one week data were col-
lected a week after the injection (before exercise
started) and hence represent the efficacy of injection
alone. Information was also collected on the concomi-
tant use of analgesics.
After 12 weeks the randomised trial finished and all
patientsreceivedusualcare.Follow-upby postalques-
tionnaire at 24 weeks ascertained if improvement in
the groups was maintained. The treating physio-
therapist completed treatment log sheets and returned
them to the study office. Information on additional
treatments, referrals, and patients’ satisfaction was
also collected from the 24 week questionnaire and the
therapy log sheets. Treating therapists were also asked
to complete adverse event forms.
Sample size
Williams et al found that plus or minus 10 represented
a clinically important change in the shoulder pain and
disability index.
28 We therefore calculated our sample
size on the ability to detect a difference in treatment
groups of 10 points or more in this score. Carette et al
reported standard deviations around the mean change
in scores from baseline to three months of 24.3 for
those receiving a combination of steroid injections
andphysiotherapyand24.5forthosereceivingphysio-
therapyalone.
20Usingthesedata,weestimatedthatwe
needed95patientsperarmtoshowasignificantdiffer-
ence at the 5% level with 80% power. With allowance
for a 15% dropout rate, we therefore required 112
patients per arm.
Analysis
Patients’ data were analysed according to the rando-
mised group irrespective of deviations from the proto-
col. Results are presented for patients with data
available. In addition to those who were lost to fol-
low-up, some participants for whom we had data at
24 weeks either did not attend for one or more inter-
vening visits or did not fully complete the shoulder
pain and disability index. We excluded patients with
missingdataataparticulartimepointfromtheanalysis
at that time point.
Rasch transformation of pain and disability index
To provide interval scaling, we transformed the ordi-
naldatafromtheshoulderpainanddisabilityindexby
Rasch analysis, with adequate model fit (χ
2=34.46,
df=36;P=0.542)andstrictunidimensionality(indepen-
dent t test <5%).
29
Statistical tests
We had three primary outcomes of interest at the pri-
mary 12 week end point: change in total score on the
shoulder pain and disability index and in each of the
two subscales for pain and function. Secondary out-
comes included change in the three measures on the
shoulder pain and disability index at each of the sec-
ondary end points, patients’ global assessment of
change at each end point, and subgroup analyses of
patients in the exercise only group who subsequently
required an injection. We analysed covariance of
changes in shoulder pain and disability index mea-
sures, taking baseline values as covariates. We used
Pearson’s χ
2 tests to compare patients’ global assess-
ment of change between groups and an independent
Student’s t test to compare total shoulder pain and dis-
ability index at week 12 between patients in the exer-
cise only group who subsequently required an
injectionandthosewhodidnot.Bonferronicorrection
for multiplecomparisonsset the critical significance to
P<0.005 for secondary analysis of covaraince and to
P<0.0125 for Pearson’s χ
2 tests. Analyses were carried
out in SPSS 16.0.2.
RESULTS
Over 30 months we screened 1588 referrals for
shoulder pain (figure). Of the 232 participants
included, 115 were randomised to subacromial injec-
tion plus exercise and 117 to exercise only. Baseline
characteristics were similar in both groups (table 1),
though patients in the exercise only group had slightly
Table 1 |Baseline characteristics of participants with subacromial impingement syndrome
according to treatment group. Figures are numbers (percentages) unless stated otherwise
Exercise only
(n=117)
Injection plus exercise
(n=115)
Mean (SD) age (years) 54.9 (10) 57.2 (10.3)
Women 67/117 (57) 60/115 (52)
Median (IQR) weeks of shoulder pain 17 (12-28) 14 (10-26)
First episode of shoulder pain 81 (69) 78 (68)
Started after injury 29 (25) 29 (25)
Employed 89 (76) 72 (63)
Diabetic 8 (7) 9 (8)
Taken painkillers in previous 48 hours 58 (50) 60 (52)
Mean (SD) shoulder pain and disability index:
Total 47.26 (9.65) 46.25 (7.84)
Pain 52.02 (9.91) 50.21 (8.13)
Function 42.49 (11.05) 42.29 (8.52)
IQR=interquartile range.
RESEARCH
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beemployed.Fourteenpatients(eightin injectionplus
exercise group;six in exercise only group) were lost to
follow-up before the 12 week visit. Twelve patients
(seven and five, respectively) did not attend the week
12 visit, and one patient in the injection plus exercise
group did not fully complete the shoulder pain and
disability index. Data from the 12 week questionnaire
were therefore available for 205 (88%). A total of 26
patients (13 in each group) did not return the 24 week
questionnaire, and 13 patients (six and seven, respec-
tively)didnotfullycompletethequestionnaireatweek
24. Data from the 24 week questionnaire were there-
foreavailablefor193 (83%).The27 patientswhowere
notincludedintheanalysisoftheprimaryoutcomesat
12 weeks were slightly younger than those with data
available (mean age 51.0 (SD 9.4) v 56.7 (SD 9.9)) but
a comparable proportion were women (15/27 (56%) v
112/205 (55%) and had experienced shoulder pain of
similar duration on entry to the study (median
16weeksforboth),andtheydidnotdiffersubstantially
in terms of baseline total index score (mean 46.3 (SD
4.9)v46.8(SD9.2)),painsubscalescore(49.9(SD5.7)v
51.3 (SD 9.5)), or function subscale score (42.8 (SD
30.9) v 42.3 (SD 10.3)).
Compliance with protocol
In the injection plus exercise group 114 participants
received one injection, and four participants received
a second injection. One participant randomised to the
injection plus exercise group did not receive any
treatment because of non-attendance. One participant
in the exercise only group did not attend for any treat-
ment.Sixparticipantsintheexerciseonlygroupfound
theirpainintolerableandoptedtohaveasteroidinjec-
tionbefore12weeks.Twoparticipantsinthecombina-
tion groupreceivedaninjectionbut didnot attendany
physiotherapy appointments. Two hundred treatment
logswerereturned(98ininjectionplusexercisegroup;
102 in exercise only group). The treatment logs indi-
cated that all patients underwent an exercise pro-
gramme. Some patients did not receive manual
therapy (10/98 in injection plus exercise; 5/102 in
exercise only group). The 28 remaining participants
for whom we did not have a treatment log had their
appointment records checked and had all attended at
leastonesessionofphysiotherapy.Participantsinboth
groups attended a median of six physiotherapy ses-
sions.
Primary outcome
Table 2 shows the change in mean scores on the
shoulder pain and disability index over time. At week
12 there was no significant difference between the
groups for the pain subscale, disability subscale, or
total score. Addition of duration of symptoms and
employment status as covariates did not affect the
results nor did adjusting for additional steroid injec-
tions required by patients in the exercise only group
(data not shown).
For comparison with the Rasch transformed data,
theadjustedmeanchangeintheoriginaltotalshoulder
Table 2 |Change in mean scores on shoulder pain and disability index over time
Change in mean score (95% CI)
Difference (95% CI) P value Exercise only Injection plus exercise
Week 1
No of patients 108 104 ——
Score:
Total −1.53 (−3.11 to 0.056) −8.08 (−9.69 to −6.47) 6.56 (4.30 to 8.82) <0.001
Pain −1.01 (−2.68 to −0.66) −9.04 (−10.74 to −7.33) 8.02 (5.64 to 10.41) <0.001
Disability −2.01 (−3.68 to −0.34) −7.16 (−8.86 to −5.46) 5.15 (2.77 to 7.53) <0.001
Week 6
No of patients 103 99 ——
Score:
Total −6.88 (−8.99 to −4.76) −14.24 (−16.40 to −12.09) 7.37 (4.34 to 10.39) <0.001
Pain −7.29 (−9.57 to −5.02) −15.02 (−17.34 to −12.71) 7.73 (4.48 to 10.98) <0.001
Disability −6.43 (−8.57 to −4.29) −13.50 (−15.68 to −11.31) 7.07 (4.01 to 10.12) <0.001
Week 12
No of patients 106 99 ——
Score:
Total −13.09 (−15.92 to −10.26) −16.35 (−19.28 to −13.43) 3.26 (−0.81 to 7.34) 0.116
Pain −13.29 (−16.39 to −10.19) −17.11 (−20.31 to −13.91) 3.82 (−0.65 to 8.29) 0.093
Disability −12.83 (−15.59 to −10.06) −15.74 (−18.59 to −12.90) 2.92 (−1.05 to 6.88) 0.149
Week 24
No of patients 97 96 ——
Score:
Total −17.05 (−20.23 to −13.88) −14.79 (−17.99 to −11.60) −2.26 (−6.77 to 2.25) 0.324
Pain −16.67 (−19.94 to −13.40) −14.53 (−17.86 to −11.19) −2.14 (−6.83 to 2.54) 0.368
Disability −16.87 (−20.00 to −13.74) −14.90 (−18.03 to −11.76) −1.98 (−6.40 to 2.45) 0.380
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exercise only group and −28.54 in the exercise plus
injection group (P=0.111). Though Rasch transform-
ing the score to interval scaling resulted in smaller
mean changes in both groups, the difference between
the groups was of similar magnitude (original mean
4.94 (95% confidence interval −1.15 to 11.03) v Rasch
3.26 (−0.81 to 7.34)).
Secondary outcomes
At week 24 there continued to be no significant differ-
ence between the groups for the pain subscale, disabil-
itysubscale,ortotalscore.Adjustmentforthenecessity
for additional steroid injections in the exercise only
group during the 24 weeks of follow-up did not affect
the results (data not shown). Improvement was signifi-
cantly greater in the injection plus exercise group at
week 1 and 6.
Table 3 shows participants’ global assessment of
overall change compared with baseline. At week 1,
50/104 (48%) reported recovery or improvement in
the exercise only group compared with 75/97 (77%)
in the injection plus exercise group. At week 6, 78/
100 (78%) reported recovery or improvement in the
exercise only group compared with 86/94 (92%) in
the combined injection plus exercise group. By week
12 and 24 the percentage of participants reporting
recovery or improvement was similar in both groups.
At12weeks,however,therewasstillahighercomplete
recovery rate in the injection plus exercise group than
in the exercise only group (15/101 v 8/104).
At24weekstheproportionstilltakingpainkillersfor
their shoulder pain was higher in the exercise only
group than in the injection plus exercise group (39/
102 (38%) v 28/100 (28%)). Table 4 shows the addi-
tional treatments required in both groups. In the exer-
ciseonlygroup37patientswentontohaveaninjection
after the 12 week visit compared with nine patients in
theinjectionplusexercisegroup.Thoseintheexercise
only group who had an injection had a higher mean
score on the total shoulder pain and disability index at
12 weeks (n=37, mean score 40.6, 35.9 to 45.4) than
those who did not (n=69, mean score 30.6, 26.9 to
34.3) (independent Student’s t test −3.28, P=0.001).
These patients also showed a smaller improvement
from baseline (−7.2 (−11.9 to −2.5) in those who
received an injection v −16.6 (−20.0 to −13.4) in those
who did not; F=10.10, P=0.002). Most participants
reported they were satisfied or very satisfied with
their care over 24 weeks (91/97 (94%) in injection
plus exercise group; 93/104 (90%) in exercise only
group). No adverse events were reported in either
group.
DISCUSSION
In this large pragmatic randomised trial on the man-
agement of subacromial impingement syndrome by
physiotherapists we found no significant difference in
the score on the shoulder pain and disability index at
three months in participants who received a combina-
tionofinjectionandexercisecomparedwiththosewho
received exercise therapy alone. In agreement with
two other studies investigating single treatments in
the management ofshoulder pain,we found outcomes
atsixmonthweresimilarinbothgroups.
78Therewere,
however, differences between groups for our second-
ary outcomes. Significantly earlier improvements in
pain and functional disability at one and six weeks
were seen in the group given corticosteroid injection
combined with exercise therapy.
Results in context
Our findings add to the current evidence base, includ-
ingaheadtoheadcomparisonofexercisetherapypre-
scribedbyaphysiotherapistwithlocalsteroidinjection
delivered by a general practitioner, which found simi-
lar outcomes at six weeks and six months.
7 Although
Table 3 |Participants’ global assessment of change from baseline
Outcome Exercise only Injection plus exercise P value*
Week 1
No of patients 104 97
Completely recovered 0 3 (3)
χ
2=24.0, P<0.001
Improved but still some problems 50 (48) 72 (74)
No change 40 (39) 21 (22)
Worse 13 (13) 1 (1)
Much worse 1 (1) 0
Week 6
No of patients 100 94
Completely recovered 1 (1) 8 (9)
χ
2=14.6, P=0.006
Improved but still some problems 77 (77) 78 (83)
No change 15 (15) 6 (6)
Worse 7 (7) 1 (1)
Much worse 0 1 (1)
Week 12
No of patients 104 101
Completely recovered 8 (8) 15 (15)
χ
2=5.4, P=0.248
Improved but still some problems 81 (76) 70 (71)
No change 11 (10) 12 (12)
Worse 5 (5) 1 (1)
Much worse 1 (1) 1 (1)
Week 24
No of patients 104 101
Completely recovered 17 (16) 16 (16)
χ
2=2.3, P=0.672
Improved but still some problems 69 (66) 71 (70)
No change 10 (10) 11 (11)
Worse 5 (5) 2 (2)
Much worse 3 (3) 1 (1)
*For change compared with baseline.
Table 4 |Additional treatments and referrals
Additional interventions
Exercise only
(n=117)
Injection plus
exercise (n=115)
Injection before 12/52 6 (5) —
Injection after 12/52 37 (32) 9 (9)
Ultrasound guided
injection
13 (11) 7 (6)
Ultrasound scan 9 (8) 9 (8)
Orthopaedic referral 9 (8) 8 (7)
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at12weeks,weidentifiedthepartialimproversornon-
improversby monitoringthe additionalinjectionsthat
participants required once the randomised trial fin-
ished after 12 weeks, when usual care resumed. In the
exercise only group there was a significantly higher
week 12 score on the shoulder pain and disability
indexforthoseparticipantswhorequiredasubsequent
injection from 12-24 weeks compared with those who
were treated only with exercise therapy. Results from
the current study would suggest that about a third of
adults with impingement and moderate or severe
shoulder pain will not respond adequately to exercise
therapy alone within three months.
Inexaminingresultsfromrecenthighqualityrando-
mised controlled trials for common musculoskeletal
problems, Foster et al commented on the trend for no
or very small differences between the effectiveness of
different approaches when based on long term out-
comes (6-12 months).
30
Shorter term outcomes might, of course, be more
relevant to people disabled with shoulder pain and to
practitioners deciding which treatment to choose in
clinicalpractice.ArecentUKtrialcomparingcorticos-
teroidinjectionwithlocalanaestheticinjectionforrota-
tor cuff problems also highlighted the importance of
looking at early outcomes.
31 It was for this reason that
we included a one week outcome measure in the cur-
rentstudy.Wenotedrapidimprovementfromthester-
oid injection at one week, and the combined injection
and exercise protocol resulted in significantly greater
improvement in pain and functional disability at six
weeks. If early pain relief is a priority, then adding
local steroid injection to a course of physiotherapy
would seem to be the best option for patients.
In our trial all therapies were delivered by physio-
therapists working in a primary care based musculos-
keletal service, and no extra NHS resources were
required to implement the study interventions. In rou-
tine clinical practice in the UK, combining these treat-
ments in a timely fashion could be problematic for
practical reasons related to the skills of practitioners
and service issues such as waiting lists for physio-
therapy. In this study physiotherapists provided both
arms of the study; in other large trials different profes-
sions have provided the treatment arms.
7-931
The need to avoid selection of a heterogeneous
group in research into shoulder pain has been
highlighted.
32 Although clinical classification is diffi-
cult, we aimed to exclude conditions for which the
study protocol was not appropriate, such as adhesive
capsulitisandinflammatoryarthritis,andpatientswith
mild shoulder pain and those aged under 40 years.
Severe shoulder pain at initial presentation has been
shown to be a prognostic indicator for persistent
symptoms.
3334 In keeping with two previous studies
that excluded patients with low scores on the shoulder
pain and disability index
2035 we deliberately included
only patients who rated their pain as moderate or
severe because patients with mild pain would not rou-
tinely be offered an injection in clinical practice. Of
those patients not eligible for the study, 152 (17%)
reported mild shoulder pain. Other studies investigat-
ing corticosteroid injections have not used the level of
pain or degree of functional disability as specific entry
criteria.
36-41Weexcludedpatientsaged40andunderto
avoid including younger patients with subacromial
impingement related to a sporting injury, who are not
usuallyofferedsteroidinjectionsasaninitialtreatment,
which was the consensus view of the physiotherapists
whodesignedtheinterventionpackage.Arecentstudy
indicated that nearly 80% of shoulder pain is found in
patients aged40 and over
2; our studytherefore reflect-
ing the age group with the highest prevalence of
shoulder pain.
Limitations of study
Because of this study’s pragmatic design, participants
werenotblindedtotheirinterventionsandtherecould
have been a placebo or non-specific effect caused by
the injection. We therefore accept that the total treat-
ment response probably includes both treatment and
associatedplaceboeffects,as isthe case in routineclin-
ical practice.
42 We did not set out to examine which
component of the non-pharmacological intervention
(exercise or manual therapy, or both) is effective.
Although evidence is emerging about the efficacy of
certain interventions—for example, exercise com-
bined with manual therapy seems more effective than
exercise alone for subacromial impingement
syndrome,
2526 and ultrasound guided injections might
have better outcomes than “blind” injections
43—ques-
tions about the optimal use of injection and physio-
therapy interventions remain and continue to be
important for future research.
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